GENERIC NAME: radium Ra 223 dichloride
BRAND NAME: Xofigo
DRUG CLASS AND MECHANISM: Radium Ra 223 (Xofigo) is a radioactive medicine (radiotherapeutic drug) that is used to treat male patients with symptoms of advanced prostate cancer that has spread to the bones, but not to other parts of the body. The radioactive particles emitted by radium Ra 223 helps kill cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells. Radium Ra 223 can help some patients live longer. Compared to placebo, radium Ra 223 extended life by 14.9 months vs. 11.3 months for the placebo group. The FDA approved Radium Ra 223 in May 2013.
PRESCRIBED FOR: Radium Ra 223 is used for treating symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to other parts of the body. Radium Ra 223 should only be used by male patients.
SIDE EFFECTS: The most common side effects of radium Ra 223 are:
- swelling of the arms or legs (peripheral edema), and
- low blood cell counts.
Quick GuideProstate Cancer Symptoms, PSA Test, Treatments
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.